MarginsXMarginsX
Home › Markets › Health Care › EOLS

Evolus Inc. (EOLS)

EOLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.63
-4.74% on the day
Market cap
$438.8M
Small cap
Revenue · 2025
$297.2M
+11.6% on 2024
Net income · 2025
-$51.6M
-17.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1570562/000162828026014001/0001628280-26-014001-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerEOLS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001570562
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$297.2M
Net income-$51.6M
Operating income-$32.7M
Net margin-17.4%
Operating margin-11.0%
Revenue growth+11.6%
Cash$53.8M
Total assets$225.9M
P/E (computed)Net income was not positive
P/S (computed)1.5×

Warning signs

Cash runway
189.2 months
$41.7M cash at September 30, 2026
Share count, 1 year
+2.1%
2025-10-31 to 2026-10-30 · +15.8% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$1.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$41.7M cash; operating cash flow -$661K a quarter.Report 2026-09-30
Shares outstanding66,188,366 (2026-10-30); 64,819,784 a year earlier; 57,150,722 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$78.0M-$12.5M-$1.9M$41.7M$156.9M$325.5M10-Q 2026-11-04
Q2 2026
2026-06-30
$84.1M-$8.1M-$3.6M$45.2M$156.7M$316.5M10-Q 2026-08-05
Q1 2026
2026-03-31
$73.1M-$10.7M-$10.0M$49.8M$156.4M$301.8M10-Q 2026-05-04
Q4 2025
2025-12-31
$90.3M$130K$12.8M$53.8M$146.1M$297.2M10-K 2026-03-03
Q3 2025
2025-09-30
$69.0M-$15.7M-$14.7M$43.5M$145.8M$285.8M10-Q 2026-11-04
Q2 2025
2025-06-30
$69.4M-$17.1M-$24.8M$61.7M$145.5M$277.9M10-Q 2026-08-05
Q1 2025
2025-03-31
$68.5M-$18.9M-$15.6M$67.9M$121.8M$275.5M10-Q 2026-05-04
Q4 2024
2024-12-31
$78.9M-$6.8M$4.8M$87.0M$121.5M$266.3M10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-06-05
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 558 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.3%
1 month-7.3%
3 months-13.2%
Year to date+4.7%
1 year-5.6%
From 52-week high-25.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
ARVNArvinas Inc.$6.77-0.73%$443.3M
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
DMACDiaMedica Therapeutics Inc.$8.33-5.23%$449.5M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier